KEYNOTE-054: Analysis of Crossover and Rechallenge With Pembrolizumab in Recurrent Patients After Complete Resection of High-Risk Stage III Melanoma

June 4-8, 2021; Online at https://conferences.asco.org/am
In KEYNOTE-054 Part 2, PFS and ORR after recurrence and crossover to pembrolizumab were similar to previous studies of immune checkpoint therapy for advanced melanoma, but pembrolizumab rechallenge had minimal activity.
Format: Microsoft PowerPoint (.ppt)
File Size: 2.39 MB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Related Content

CheckMate 915: association of ctDNA and other translational factors at baseline with RFS in patients with stage IIIB-D/IV melanoma receiving adjuvant immunotherapy, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 23, 2022

Phase II SWOG S1801 study: neoadjuvant vs adjuvant treatment with pembrolizumab in patients with resectable stage III-IV melanoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 23, 2022

Additional response results from RELATIVITY-047 evaluating the addition of relatlimab to nivolumab vs nivolumab in advanced melanoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings